晚期黑色素瘤患者接受抗PD-1治疗期间急性肾损伤的真实世界研究
RAASi、既往CKD和抗PD-1累积剂量为AKI独立危险因素,AKI未影响总生存。
要点
- 抗PD-1治疗晚期黑色素瘤患者AKI发生率为17%,以肾前性为主。
- RAASi、既往CKD和抗PD-1累积剂量是AKI的独立危险因素。
- 免疫相关肾小管间质性肾炎罕见(3.3%),AKI未影响总生存。
核心结论
- 抗PD-1治疗晚期黑色素瘤患者AKI常见但多为肾前性,RAASi促进其发生,肾脏免疫相关不良事件罕见。
- PPI和糖皮质激素与较差生存相关,超重/肥胖为保护因素。
研究设计与样本
- AKI按KDIGO标准定义,通过病历回顾确定病因,分析总生存、无AKI生存及AKI对生存的影响。
主要发现
- AKI独立危险因素为使用RAASi、既往CKD和抗PD-1累积剂量。
- AKI主要病因为肾前性,仅8例(3.3%)发生急性间质性肾炎,8%患者发生CKD。
- 中位总生存为13.4个月,未受AKI影响。
- 多因素分析中,超重和肥胖患者总死亡风险较低,使用PPI或糖皮质激素者总死亡风险较高。
临床怎么用
- 接受抗PD-1治疗的晚期黑色素瘤患者应监测肾功能,尤其使用RAASi或既往存在CKD者。
- 发生AKI时首先评估肾前性因素,肾小管间质性肾炎虽罕见仍需警惕。
局限性
- 单中心回顾性研究,样本量有限,结果需外推验证。
- AKI病因基于病历回顾判断,可能存在信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoints inhibitors have transformed the prognosis of advanced melanoma but are associated with immune-related adverse events (irAEs). We evaluated the incidence, risk factors and causes of acute kidney injury (AKI) in a monocentric real-life cohort of patients treated with anti-programmed death receptor-1 (anti-PD1) antibodies for advanced melanoma. METHODS: Retrospective collection of medical charts and comprehensive analysis of lab results from patients treated with nivolumab or pembrolizumab for advanced melanoma between 2014 and 2018 was carried out. AKI was defined by Kidney Disease Improving Global Outcomes criteria, and causes were determined by chart review. Overall survival, survival without AKI and impact of AKI on survival were analysed. Risk factors for death and for AKI were identified. RESULTS: Two hundred and thirty-nine patients were included. Forty-one (17%) had at least one episode of AKI. Independent risk factors for AKI were treatment with renin-angiotensin-aldosterone system inhibitors (RAASi), pre-existing chronic kidney disease (CKD) and cumulated doses of anti-PD1. The main cause of AKI was prerenal, and only eight patients (3.3%) developed acute interstitial nephritis; 8% of patients developed CKD. The median overall survival was 13.4 months and was not affected by AKI. In multivariate analysis, the overall mortality was lower in overweight and obese patients and higher in patients treated with proton-pump inhibitors (PPI) or corticosteroids. CONCLUSIONS: AKI is common in patients treated with anti-PD1 for advanced melanoma but is mostly prerenal and favoured by the use of RAASi; renal irAE is rare. PPI and corticosteroids were associated with poor survival in this population, while overweight/obesity was protective.
引用
- Stein C, Burtey S, Mancini J, et al. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant. 2021. PMID: 32941608. doi:10.1093/ndt/gfaa137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。